| Nasrullah Undre
| INTRODUC TI ON
Transplantation, now a routine procedure for end-stage liver, kidney, or heart disease, is associated with excellent long-term survival rates (>80%) in pediatric populations. 1 Approximately 25% of patients undergoing liver or heart transplantation are aged ≤1 year, with 39% of pediatric liver and 22% of pediatric heart transplantations occurring in children aged 1-5 years. 1, 2 Successful transplantation is dependent on an effective immunosuppression regimen and is often based on tacrolimus. 2, 3 Although extemporaneously prepared suspensions of the tacrolimus capsule contents have been used in children, they have inherent limitations in terms of batch-to-batch variability and short stability. [3] [4] [5] Tacrolimus granules (Modigraf ® ) were developed to address an unmet medical need, specifically for patients unable to swallow intact capsules. The mean oral bioavailability of tacrolimus granules has been shown to be 26% ± 23% (range 4%-80%). 6 Tacrolimus in granule formulation was approved in Japan in 1998 and in Europe in 2009, and is available as 0.2 and 1 mg sachets that can be suspended in water and administered orally.
6
Clinical studies have established that achieving a sufficient systemic exposure to tacrolimus (AUC) is an important variable associated with efficacy. However, monitoring tacrolimus AUC to optimize the dose is not practical in routine clinical care, thus C trough is used as a surrogate marker of AUC for TDM. 7, 8 The relationship between C trough and AUC has been established for capsule formulations of tacrolimus in adult and pediatric populations; [8] [9] [10] [11] [12] corresponding data for tacrolimus granules are limited. Here, we report PK data for tacrolimus granules in children undergoing de novo liver, kidney, or heart transplantation.
| MATERIAL S AND ME THODS

| Study design
This was a multicenter, single-arm, phase IV PK study of tacrolimus granules in children undergoing de novo liver, kidney, or heart transplantation. The study was conducted across 10 sites in six countries: United Kingdom, Spain, Germany, Belgium, Poland, and France (NCT01371331, https://clinicaltrials.gov). The Independent Ethics
Committee/Institutional Review Board reviewed the ethical, scientific, and medical appropriateness of the study, and approval for the study protocol was obtained from the relevant competent authorities at each study site, prior to study initiation. For all study subjects, the patient's parent(s) or their legal representative(s) had been fully informed and had given written informed consent to participate in the study. The patient had given assent where applicable. All procedures performed during this study were in accordance with the 1975 Declaration of Helsinki and its later amendments or comparable ethical standards.
| Patients
Eligible patients were ≤12 years of age and first-time recipients of a liver, kidney, or heart transplant. Patients were permitted to have received a multiorgan transplant. Exclusion criteria included: high immunologic risk (panel reactive antibody score >50% in the previous 6 months for kidney transplant recipients); significant renal impairment (serum creatinine ≥230 μmol/L [≥2.6 mg/dL] pretransplantation in liver and heart transplant recipients); or liver disease (elevated alanine aminotransferase, and/or aspartate aminotransferase, and/ or total bilirubin levels three times the upper limit of normal during the 28 days prior to transplantation) in kidney and heart transplant recipients.
| Intervention
Transplant recipients were treated with tacrolimus granules (Astellas Pharma, Tokyo, Japan) at an initial daily dose of 0.3 mg/kg per day, given as two doses (0.15 mg/kg twice daily) postoperatively. When the total daily dose was not divisible by 0.2 (the smallest sachet size), the dose was rounded up by 0.1 mg. In cases where it was not possible to divide the daily dose exactly, the higher dose was given in the morning. The first dose of tacrolimus 0.15 mg/kg was administered in the morning within 24 hours of reperfusion (this period could be extended up to 5 days for heart transplant recipients, if required).
Subsequent oral tacrolimus doses were adjusted based on clinical evidence of efficacy and the occurrence of TEAEs, aided by TDM, to maintain C trough in the recommended range of 5-20 ng/mL using site-specific assays.
| Preparation of tacrolimus granules suspension for dosing
Centers were advised to prepare the tacrolimus granules suspension by adding the contents of the tacrolimus granule sachets to a measured volume of water (maximum of 50 mL) in a glass or cup; materials containing polyvinyl chloride were avoided for all dosing procedures.
The mixture was then stirred gently until the granules were completely suspended. The suspension was drawn up with a syringe and administered orally; alternatively, the contents of the glass or cup were swallowed directly by the transplant recipient. The glass or cup was then rinsed and filled with an equal amount of water to the suspension to be consumed by the transplant recipient. Other methods of delivery, such as through a gastrostomy tube, were not permitted. 
| Concomitant medications
| Pharmacokinetic evaluation
Whole blood samples (0. Blood samples were thawed, and 0.2 mL aliquots were taken for analysis. The assay was based on the method developed by Alak et al. 13 Aliquots were extracted using protein precipitation and solidphase extraction using C18 200 mg/3 mL cartridges. Elutes were evaporated to dryness under a stream of nitrogen at 40°C, and residues were re-dissolved in a 50:50 mix (vol/vol) of acetonitrile and water, mixed and centrifuged, before being submitted for HPLC/ MS/MS. An analog of tacrolimus (ascomycin) was used as an internal standard. The lower limit of quantification was 0.5 ng/mL. All procedures were performed in compliance with the Principles of Good Laboratory Practice.
Tacrolimus concentrations for TDM were determined using a sitespecific HPLC/MS/MS assay or immunoassay at local laboratories.
| Outcomes
The primary objective of this study was to determine the PK of tacrolimus granules after the initial dose and at steady state in children undergoing de novo liver, kidney, or heart transplantation. The PK parameters evaluated were AUC tau , C max , t max , and C trough . All PK parameters were A post hoc analysis was conducted to examine the relationship between age and AUC tau after the first dose of tacrolimus 0.15 mg/kg for all transplant recipients.
| Statistical analyses
No power calculations were performed; however, based on previous experience, and assuming a drop-out rate of 40%, approximately 60 transplant recipients were required to achieve 36 evaluable transplant recipients (12 [±2] from each transplant group), each with two evaluable PK profiles.
The SAF consisted of all transplant recipients who took at least one dose of study medication. The PKAS included all transplant recipients who provided two evaluable PK profiles (after the first dose of tacrolimus and at steady state).
For continuous variables, descriptive statistics included the number of transplant recipients, mean, SD, median, minimum, and maximum. In addition, for the PK parameters AUC tau and C max (and any other PK parameter determined, except t max ), the coefficient of variation and geometric mean were calculated. If C max occurred at more than one time point, the first time it occurred was considered for t max . Frequencies and percentages were displayed for categorical data.
Data were analyzed by type of organ transplant and overall. All data processing, summarization, and analyses were performed using SAS ® version 9.1.3 or higher on UNIX.
| RE SULTS
| Patients
Trial enrollment commenced on June 9, 2011; 53 patients were screened, of whom 52 received transplants and treatment with tacrolimus granules (Figure 1 were aged <5 years, and 17 transplant recipients (32.7%) were aged <2 years. The mean age distribution and weight of transplant recipients was lower in the liver transplant group than in the kidney and heart transplant groups (Table 1 ). All kidney transplant recipients were aged between 2 and 11 years, and no patients were multiorgan transplant recipients. Mean (±SD) whole blood concentration-time profiles after the first dose of tacrolimus and at steady state are shown in Figure 2 . C max was observed approximately 1 hour after drug dosing for all transplant groups after the first dose of tacrolimus and at steady state.
| PK profile and exposure
In the PKAS, the mean initial dose of tacrolimus was 0.15 mg/kg for all transplant recipients; corresponding values at steady state were 0.18 mg/kg for liver, 0.16 mg/kg for kidney, and 0.14 mg/kg for heart transplant recipients.
After the first dose of tacrolimus, mean AUC tau was approximately twofold higher in children who received a liver or heart transplant (211 and 224 hour*ng/mL, respectively) compared with those who received a kidney transplant (97 hour*ng/mL) ( Figure 3) . Overall, mean AUC tau was 163 hour*ng/mL in children aged <5 years and 209 hour*ng/mL in those aged ≥5 years (Table 2) . At steady state, mean AUC tau was 195 hour*ng/mL in children who received a liver transplant, 208 hour*ng/mL in children who received a kidney transplant, and 165 hour*ng/mL in children who received a heart transplant ( Figure 3 ). Mean AUC tau at steady state was 185 hour*ng/mL in children aged <5 years and 199 hour*ng/mL in those aged ≥5 years (Table 3) . A post hoc analysis found a low correlation (Pearson's coefficient: r = 0.11; P > 0.5) between age (range: 0.3-12.5 years) and AUC tau at a fixed dose of tacrolimus 0.15 mg/kg (Figure 4 ).
Overall, there was a strong correlation between the C trough of tacrolimus in whole blood and AUC after the first dose of tacrolimus and at steady state (Pearson's coefficient: r = 0.81 and r = 0.87, respectively; P < 0.01; Figure 5 ).
The mean (SD) C trough level of tacrolimus over the 2-week study period was 11.7 (4.2) ng/mL (14.9 [4.5] ng/mL in liver, 9.6 [2.1] ng/mL in kidney, and 9.8 [2.9] ng/mL in heart transplant recipients). In the SAF, the mean (SD) C trough level of tacrolimus was similar in both age subgroups (11.6 [3.9] ng/mL in transplant recipients aged <5 years and
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TA B L E 1 Demographic and baseline characteristics (SAF)
11.9 [5.1] ng/mL in transplant recipients aged ≥5 years). The mean daily dose of tacrolimus was reduced from Day 2 in liver and heart transplant recipients to maintain required C trough levels ( Figure 6 ).
Secondary end-points are summarized in heart transplant recipients, respectively. In this study of tacrolimus granules in pediatric transplant recipients, the mean AUC tau after the first dose of tacrolimus was approximately twofold higher in liver and heart transplant recipients than in kidney transplant recipients, suggesting a higher clearance or lower oral bioavailability of tacrolimus in children with kidney transplants. 14 Observations from studies in adult liver, kidney, and heart transplant recipients have reported similar differences in systemic exposure among these recipients. Furthermore, studies in adult transplant recipients receiving intravenous tacrolimus TA B L E 2 Summary of PK parameters by age group: first dose of tacrolimus (PKAS) TA B L E 3 Summary of PK parameters by age group: steady state (PKAS)
showed a higher clearance in kidney transplant recipients compared with liver transplant recipients. 17, 18 The C max of tacrolimus was observed approximately 1 hour after dosing across all transplant types, indicating that tacrolimus granules were rapidly absorbed. This is similar to the t max of oral tacrolimus (~2 hours) observed in other studies in pediatric liver and kidney transplant recipients.
9,10
The safety and efficacy of tacrolimus granules was established in a 12-month, open-label, parallel-group, randomized phase III study of children who had undergone liver transplantation. 19 Treatment with tacrolimus granules, combined with corticosteroids, showed superiority over treatment with a ciclosporin A microemulsion combined with corticosteroids and azathioprine (acute rejectionfree rate at Month 12 in the tacrolimus granules vs ciclosporin A groups was 55.5% vs 40.2%, respectively; P = 0.03) with a similar incidence of TEAEs. 19 In our study, the efficacy and TEAE profile of tacrolimus granules were similar to other tacrolimus studies over the first 2 weeks of exposure. However, owing to the short duration of observation, it is difficult to interpret the safety of tacrolimus granules in this study. A long-term study is underway to evaluate the safety and efficacy of tacrolimus granules in pediatric solid allograft recipients.
| CON CLUS IONS
In this study, the PK profile of tacrolimus granules in de novo pediatric transplant recipients has demonstrated a strong correlation between C trough and AUC tau . In pediatric transplantation, C trough may be used as a reliable marker for monitoring tacrolimus exposure within the first 2 weeks post-transplantation. TA B L E 4 Summary of secondary end-points (SAF)
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